Matches in SemOpenAlex for { <https://semopenalex.org/work/W2277911044> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2277911044 endingPage "6" @default.
- W2277911044 startingPage "393" @default.
- W2277911044 abstract "This phase I study is to determine the maximal tolerated dose and the dose-limiting toxicity of capecitabine combined with standard radiotherapy (RT) as postoperative adjuvant treatment for rectal cancer patients.Stage II/III rectal cancer patients 18 - 75 years of age had undergone curative surgery with Karnofsky score > or = 70% were eligible to be included in this study. Total dose of RT DT 50 Gy was delivered to the pelvic area in fraction of 2.0 Gy per day for 5 weeks. Capecitabine was orally administered concurrently with radiotherapy for a total of 2 cycles in escalating doses: twice daily at 12 hour interval for consecutive 14 days as one cycle, separated by a seven day rest, then followed by another cycle. From March 2004 to May 2005, 24 patients were included and treated at the following dose levels: daily 1000 mg/m(2) (3 patients), 1200 mg/m(2) (3 patients), 1400 mg/m(2) (3 patients), 1500 mg/m(2) (3 patients), 1600 mg/m(2) (6 patients), and 1700 mg/m(2) (6 patients). Dose-limiting toxicities (DLT) including grade 3 or grade 4 hematologic and nonhematologic toxicity were observed.Dose-limiting toxicity was observed in one patient treated at dose of 1600 mg/m(2) with grade 3 diarrhea, and in 2 patients at dose of 1700 mg/m(2) with one grade 3 and one grade 4 diarrhea.Diarrhea is the most common dose-limiting toxicity. In our study, the maximal tolerated dose (MTD) of capecitabine given concurrently with radiotherapy was daily 1600 mg/m(2), from D1 to D14 separated by 7-day rest for 2 cycles. Capecitabine given concurrently with standard radiotherapy is safe and tolerable for operated stage II/III rectal cancer patients." @default.
- W2277911044 created "2016-06-24" @default.
- W2277911044 creator A5015924742 @default.
- W2277911044 creator A5031810848 @default.
- W2277911044 creator A5050067556 @default.
- W2277911044 creator A5052086393 @default.
- W2277911044 creator A5067714130 @default.
- W2277911044 creator A5082156574 @default.
- W2277911044 creator A5086326013 @default.
- W2277911044 date "2006-05-01" @default.
- W2277911044 modified "2023-09-22" @default.
- W2277911044 title "[Phase I study of postoperative concurrent chemoradiation with capecitabine as adjuvant treatment for stage II/III operable rectal cancer]." @default.
- W2277911044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17045010" @default.
- W2277911044 hasPublicationYear "2006" @default.
- W2277911044 type Work @default.
- W2277911044 sameAs 2277911044 @default.
- W2277911044 citedByCount "0" @default.
- W2277911044 crossrefType "journal-article" @default.
- W2277911044 hasAuthorship W2277911044A5015924742 @default.
- W2277911044 hasAuthorship W2277911044A5031810848 @default.
- W2277911044 hasAuthorship W2277911044A5050067556 @default.
- W2277911044 hasAuthorship W2277911044A5052086393 @default.
- W2277911044 hasAuthorship W2277911044A5067714130 @default.
- W2277911044 hasAuthorship W2277911044A5082156574 @default.
- W2277911044 hasAuthorship W2277911044A5086326013 @default.
- W2277911044 hasConcept C121608353 @default.
- W2277911044 hasConcept C126322002 @default.
- W2277911044 hasConcept C141071460 @default.
- W2277911044 hasConcept C146357865 @default.
- W2277911044 hasConcept C151730666 @default.
- W2277911044 hasConcept C2777909004 @default.
- W2277911044 hasConcept C2779802037 @default.
- W2277911044 hasConcept C29730261 @default.
- W2277911044 hasConcept C509974204 @default.
- W2277911044 hasConcept C526805850 @default.
- W2277911044 hasConcept C71924100 @default.
- W2277911044 hasConcept C86803240 @default.
- W2277911044 hasConcept C90924648 @default.
- W2277911044 hasConceptScore W2277911044C121608353 @default.
- W2277911044 hasConceptScore W2277911044C126322002 @default.
- W2277911044 hasConceptScore W2277911044C141071460 @default.
- W2277911044 hasConceptScore W2277911044C146357865 @default.
- W2277911044 hasConceptScore W2277911044C151730666 @default.
- W2277911044 hasConceptScore W2277911044C2777909004 @default.
- W2277911044 hasConceptScore W2277911044C2779802037 @default.
- W2277911044 hasConceptScore W2277911044C29730261 @default.
- W2277911044 hasConceptScore W2277911044C509974204 @default.
- W2277911044 hasConceptScore W2277911044C526805850 @default.
- W2277911044 hasConceptScore W2277911044C71924100 @default.
- W2277911044 hasConceptScore W2277911044C86803240 @default.
- W2277911044 hasConceptScore W2277911044C90924648 @default.
- W2277911044 hasIssue "5" @default.
- W2277911044 hasLocation W22779110441 @default.
- W2277911044 hasOpenAccess W2277911044 @default.
- W2277911044 hasPrimaryLocation W22779110441 @default.
- W2277911044 hasRelatedWork W1972320730 @default.
- W2277911044 hasRelatedWork W2019996091 @default.
- W2277911044 hasRelatedWork W2027716910 @default.
- W2277911044 hasRelatedWork W2028697269 @default.
- W2277911044 hasRelatedWork W2031654287 @default.
- W2277911044 hasRelatedWork W2074428919 @default.
- W2277911044 hasRelatedWork W2077546303 @default.
- W2277911044 hasRelatedWork W2079757044 @default.
- W2277911044 hasRelatedWork W2143659497 @default.
- W2277911044 hasRelatedWork W2155974403 @default.
- W2277911044 hasRelatedWork W2161061368 @default.
- W2277911044 hasRelatedWork W2163775837 @default.
- W2277911044 hasRelatedWork W2167585519 @default.
- W2277911044 hasRelatedWork W2198953748 @default.
- W2277911044 hasRelatedWork W2393966462 @default.
- W2277911044 hasRelatedWork W2403284366 @default.
- W2277911044 hasRelatedWork W3029461482 @default.
- W2277911044 hasRelatedWork W3031546577 @default.
- W2277911044 hasRelatedWork W3032799441 @default.
- W2277911044 hasRelatedWork W3029230176 @default.
- W2277911044 hasVolume "28" @default.
- W2277911044 isParatext "false" @default.
- W2277911044 isRetracted "false" @default.
- W2277911044 magId "2277911044" @default.
- W2277911044 workType "article" @default.